Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong

Chris Ka Pun Mok, Carolyn A Cohen, Samuel M.S. Cheng, Chunke Chen, Kin-On Kwok, Karen Yiu, Tat-On Chan, Maireid Bull, Kwun Cheung Ling, Zixi Dai, Susanna S Ng, Grace Chung-Yan Lui, Chao Wu, Gaya K. Amerasinghe, Daisy W Leung, Samuel Yeung Shan Wong, Sophie A Valkenburg, Malik Peiris, David S Hui
doi: https://doi.org/10.1101/2021.10.28.21265635
Chris Ka Pun Mok
1The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China
2Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn A Cohen
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel M.S. Cheng
4School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunke Chen
1The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China
2Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kin-On Kwok
1The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Yiu
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tat-On Chan
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maireid Bull
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kwun Cheung Ling
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zixi Dai
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanna S Ng
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grace Chung-Yan Lui
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
6Stanley Ho Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chao Wu
7Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaya K. Amerasinghe
7Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisy W Leung
8Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Yeung Shan Wong
1The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie A Valkenburg
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malik Peiris
3HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
4School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: malik@hku.hk dschui@cuhk.edu.hk
David S Hui
5Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, PR China
6Stanley Ho Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: malik@hku.hk dschui@cuhk.edu.hk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Few head-to-head evaluations of immune responses to difference vaccines have been reported.

Methods Surrogate virus neutralization test (sVNT) antibody levels of adults receiving either 2 doses of BNT162b2 (n=366) or CoronaVac (n=360) vaccines in Hong Kong were determined. An age-matched subgroup (BNT162b2 (n=49) vs CoronaVac (n=49)) were tested for plaque reduction neutralizing (PRNT) and spike binding antibody and T cell reactivity in peripheral blood mononuclear cells (PBMC).

Findings One month after the second dose of vaccine, BNT162b2 elicited significantly higher PRNT50, PRNT90, sVNT, spike receptor binding, spike N terminal domain binding, spike S2 domain binding, spike FcR binding and antibody avidity levels than CoronaVac. The geometric mean PRNT50 titres in those vaccinated with BNT162b2 and CoronaVac vaccines were 251.6 and 69.45 while PRNT90 titres were 98.91 and 16.57, respectively. All of those vaccinated with BNT162b2 and 45 (91.8%) of 49 vaccinated with CoronaVac achieved the 50% protection threshold for PRNT90. Allowing for an expected seven-fold waning of antibody titres over six months for those receiving CoronaVac, only 16.3% would meet the 50% protection threshold versus 79.6% of BNT162b2 vaccinees. Age was negatively correlated with PRNT90 antibody titres. Both vaccines induced SARS-CoV-2 specific CD4+ and CD8+ T cell responses at 1-month post-vaccination but CoronaVac elicited significantly higher structural protein-specific CD4+ and CD8+ T cell responses.

Conclusion Vaccination with BNT162b2 induces stronger humoral responses than CoronaVac. CoronaVac induce higher CD4+ and CD8+ T cell responses to the structural protein than BNT162b2.

Summary At a Glance Through the head-to-head comparison, vaccination with BNT162b2 induces significantly higher levels of SARS-CoV-2 specific binding and neutralizing antibody responses when compared to CoronaVac. CoronaVac induce higher CD4+ and CD8+ T cell responses to the structural protein than BNT162b2.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR (COVID1903003) (CKPM, SSN, GCL, MP and DSH), (COVID-190115 and COVID-190126, SAV), Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government (NRF-2018M3A9H4055203) (CKPM), US National Institutes of Health (contract no. HHSN272201400006C) (MP), National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (CKPM and MP) and RGC theme-based research scheme (T11-712/19-N and T11-705/21-N) (DSH). Research was partly supported by Fast Grant ##2161 (Emergent Ventures) to G.K.A., and NIH grants (P01AI120943, R01AI123926 to G.K.A.; R01AI107056 to D.W.L.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (Ref no: 2020.229) and all participants provided written consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding source: This research was supported by grants from the Health and Medical Research Fund Commissioned Research on the Novel Coronavirus Disease (COVID-19), Hong Kong SAR (COVID1903003) (CKPM, SSN, GCL, MP and DSH), (COVID-190115 and COVID-190126, SAV), Guangdong Province International Scientific and Technological Cooperation Projects (2020A0505100063) (CKPM), the National Research Foundation of Korea (NRF) grant funded through the Korea government (NRF-2018M3A9H4055203) (CKPM), US National Institutes of Health (contract no. HHSN272201400006C) (MP), National Natural Science Foundation of China (NSFC)/Research Grants Council (RGC) Joint Research Scheme (N_HKU737/18) (CKPM and MP) and RGC theme-based research scheme (T11-712/19-N and T11-705/21-N) (DSH). Research was partly supported by Fast Grant ##2161 (Emergent Ventures) to G.K.A., and NIH grants (P01AI120943, R01AI123926 to G.K.A.; R01AI107056 to D.W.L.).

  • Conflict of Interest We declare no competing interests.

  • Human ethics approval declaration The study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee (Ref no: 2020.229) and all participants provided written consent.

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 30, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong
Chris Ka Pun Mok, Carolyn A Cohen, Samuel M.S. Cheng, Chunke Chen, Kin-On Kwok, Karen Yiu, Tat-On Chan, Maireid Bull, Kwun Cheung Ling, Zixi Dai, Susanna S Ng, Grace Chung-Yan Lui, Chao Wu, Gaya K. Amerasinghe, Daisy W Leung, Samuel Yeung Shan Wong, Sophie A Valkenburg, Malik Peiris, David S Hui
medRxiv 2021.10.28.21265635; doi: https://doi.org/10.1101/2021.10.28.21265635
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 Vaccines in Hong Kong
Chris Ka Pun Mok, Carolyn A Cohen, Samuel M.S. Cheng, Chunke Chen, Kin-On Kwok, Karen Yiu, Tat-On Chan, Maireid Bull, Kwun Cheung Ling, Zixi Dai, Susanna S Ng, Grace Chung-Yan Lui, Chao Wu, Gaya K. Amerasinghe, Daisy W Leung, Samuel Yeung Shan Wong, Sophie A Valkenburg, Malik Peiris, David S Hui
medRxiv 2021.10.28.21265635; doi: https://doi.org/10.1101/2021.10.28.21265635

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8534)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1739)
  • Geriatric Medicine (167)
  • Health Economics (370)
  • Health Informatics (1234)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (369)
  • Infectious Diseases (except HIV/AIDS) (10271)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1666)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (262)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1757)
  • Public and Global Health (3826)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (317)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)